CritiTech Shows Small Particle Success
August 31, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech announced today that it has entered
into an agreement to perform feasibility studies for the development
of nano/micro particle compounds with a major international
pharmaceutical company. Previously, CritiTech has successfully
produced small particle compounds for this company.
“We are encouraged by the continued interest
and support demonstrated by this major company in using CritiTech’s
proprietary technology to help solve some of their drug delivery
and development challenges,” said CEO and President
Sam Campbell.
With the establishment of its new research and
commercial lab facility located at 4950 Research Park Way,
Lawrence, Kansas, CritiTech intends to expand its outreach
to the pharmaceutical industry to help address their drug
delivery and development needs. CritiTech has successfully
performed feasibility work for other pharmaceutical companies
and currently has several ongoing projects.
CritiTech provides critical drug delivery and
development technology for the pharmaceutical industry. CritiTech
produces fine-particle pharmaceuticals including nanoparticle
pharmaceuticals using patented technologies developed at the
University of Kansas. The processes use compressed carbon
dioxide as the processing medium to produce relatively residue-free
and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited substantial
interest in processes that produce improved formulations using
nanoparticulate drugs in order to extend the patent life of
an existing drug or to enable the delivery of a poorly soluble
compound. CritiTech has also successfully used its proprietary
technology to coat medicinal agents either on small particle
drugs for improved drug delivery or as a thin film on implantable
medical devices such as cardiac stents. The Nanotax™
ovarian cancer drug is the first drug to be announced under
the company’s drug development program.
|
